Phase 3 trial results show combined ixekizumab and tirzepatide therapy outperforms ixekizumab alone for patients with psoriasis and obesity or overweight.

The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far.

As Jews mark Purim and recall ancient deliverance, may this moment of upheaval deliver security for Israel and freedom for Iran’s remarkable people ...